HighTide Therapeutics Inc (2511.HK) Q4 2025 Earnings Report

HighTide Therapeutics is still in a pre-revenue, high-burn phase as of QQ4 2025, with the quarterly results recording a sizable net loss driven primarily by research and development and related operating expenses. In Q4 2025, R&D was 57,086,433 CNY and operating expenses totaled 93,938,183 CNY, yielding an EBITDA of -93,938,183 CNY and a net loss of -122,571,373 CNY (EPS -0.24). Management commentary surrounding the HTD1801 program and other pipeline assets remains a key catalyst for investors, but explicit revenue visibility remains limited. The balance sheet, however, shows a robust liquidity position: cash and equivalents plus short-term investments totaling 502,938,076 CNY, with total current assets of 532,415,682 CNY and a solid current ratio (~5.4x). Net debt runs negative (-105,567,146 CNY), underscoring substantial liquidity headroom to fund ongoing R&D and potential strategic collaborations. The company’s investment thesis hinges on successful development of HTD1801 and the broader multi-asset pipeline, offset by execution risk, clinical timelines, and financing needs to sustain operations until meaningful revenue inflection points are achieved.